Description of long-term polypharmacy among schizophrenia outpatients (Q44057877)

29 November 2017

Description of long-term polypharmacy among schizophrenia outpatients (English)

1 reference

29 November 2017

0 references

3

1 reference

29 November 2017

5

1 reference

29 November 2017

Jaana M Suvisaari

2

0 references

Jaana T Suokas

series ordinal

1

object named as

Jaana T Suokas

1 reference

29 November 2017

Pasi Korhonen

4

1 reference

29 November 2017

25 September 2012

1 reference

Social Psychiatry and Psychiatric Epidemiology

29 November 2017

1 reference

29 November 2017

48

1 reference

29 November 2017

4

1 reference

29 November 2017

631-638

1 reference

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

29 November 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

When is polypharmacy an advantage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Validation of polypharmacy process measures in inpatient schizophrenia care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Polypharmacy with second-generation antipsychotics: a review of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Antipsychotic medication coprescribing in a large state hospital system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Combination antipsychotic therapy in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Schizophrenia, neuroleptic medication and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Using prescription registries to define continuous drug use: how to fill gaps between prescriptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Geographic variation and sociodemographic characteristics of psychotic disorders in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00127-012-0586-6

Practice guideline for the treatment of patients with schizophrenia, second edition.

21 January 2018

1 reference

12 December 2020

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

1 reference

12 December 2020

Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Long-term combination antipsychotic treatment in VA patients with schizophrenia

1 reference

12 December 2020

Clinicians' reasons for antipsychotic coprescribing.

1 reference

12 December 2020

Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase

1 reference

12 December 2020

Polypharmacy in patients with schizophrenia.

1 reference

12 December 2020

Antipsychotic polypharmacy: squandering precious resources?

1 reference

12 December 2020

10.1007/S00127-012-0586-6

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

23007295